Rocket Lab (RKLB) is trading sharply lower (down about 5.85% to roughly $79.81), with price action that looks driven more by positioning than a single fresh headline. After a strong April move that included a surge tied to strategic updates and bullish positioning, the stock is seeing a reset as investors lock in gains and de-risk high-volatility names.

A key overhang is the company’s recently completed at-the-market equity offering program, which brought in about $474 million in gross proceeds and increased share count. Even when proceeds strengthen the balance sheet and fund growth, the market often treats incremental issuance as a near-term headwind—especially when the stock is priced for aggressive future execution. Investors are also weighing the stock component used in the Mynaric acquisition consideration, which adds to near-term supply concerns.

Rocket Lab’s valuation has become increasingly sensitive to confidence in the Neutron program timeline and milestone delivery. Recent months have kept attention on Neutron schedule risk following test-related issues, and the market has shown a pattern of punishing any perceived slippage or ambiguity even when other fundamentals (backlog and revenue growth) look strong.

Near-term attention shifts to Rocket Lab’s next quarterly update and any explicit schedule, testing, or customer-milestone disclosures that can reduce uncertainty around Neutron. Traders will also watch for follow-through selling tied to the recent share issuance and for whether the broader space complex stabilizes, as sentiment-driven moves have been impacting the group.